GH Research (GHRS)
(Delayed Data from NSDQ)
$8.50 USD
+0.27 (3.28%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $8.49 -0.01 (-0.12%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
GHRS 8.50 +0.27(3.28%)
Will GHRS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GHRS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GHRS
GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade
After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS)
GHRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why
Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know
How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
Other News for GHRS
Understanding Incomplete Data: A Call for Comprehensive Analyst Reports
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
Buy Rating Affirmed on GH Research Amid Anticipated Phase 2 Advances and Strong Market Potential
Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials
Maintaining Buy Rating on GH Research Amidst CEO Transition and Promising GH001 Trials